BioSpace News Archive

BioMADE today announced nine new leading-edge projects that will advance Department of Defense supply chain resiliency and sustainability goals, re-shore manufacturing jobs to the U.S

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock.

10x Genomics, Inc., a leader in single cell and spatial biology, announced the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling.

CymaBay Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants.

Phanes Therapeutics, Inc. announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company’s Clinical Advisory Board.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced the U.S. Food and Drug Administration (FDA), because of resource constraints, requires additional time to complete the Priority Review of Iovance’s Biologics License Application (BLA) for lifileucel.

The Company considers it surprising that Dr. Milner has taken active steps to oppose the deal without reviewing the full details in the Scheme Circular to be published in connection with the proposed acquisition of all of the outstanding shares of Abcam by Danaher Corporation for $24.00 per share in cash, which appears to be an attempt to create confusion for shareholders ahead of voting on the Transaction.

Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that it has entered into a license agreement with Sun Pharmaceutical Industries Limited to commercialise a first-in-class innovative drug, Tyvalzi™ in India.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its business highlights and financial results for the six-month period ending 30 June 2023 and its outlook for the remainder of the year.